BADI members only
Pharmacovigilance EU Documents 1. Directive 2001/83 EC - HERE 2. Regulation (EC) No 726/2004 (the legal framework of pharmacovigilance for medicines marketed within the EU with respect to centrally authorised medicinal products) - HERE 3. Commission Implementing Regulation (EU) No 520/2012 (on the performance of pharmacovigilance activities stipulates operational details in relation to certain aspects of pharmacovigilance to be respected by marketing authorisation holders, national competent authorities and EMA) - HERE 4. Regulation 1235/2010 (Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products Text with EEA relevance - HERE 5.Directive 2010/84/EC (Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. (Official Journal L 348, 31/12/2010) - HERE 1. Guideline on good pharmacovigilance practices (GVP) - HERE 2. Guideline on good pharmacovigilance practices (GVP) Module I – Pharmacovigilance systems and their quality systems - HERE 3. Guideline on good pharmacovigilance practices (GVP) Module II – Pharmacovigilance system master file (Rev 1)- HERE 4.Guideline on good pharmacovigilance practices (GVP) Module III - Pharmacovigilance inspections (Rev 1) - HERE 5. Guideline on good pharmacovigilance practices (GVP) Module IV – Pharmacovigilance audits (Rev1) - HERE 6. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 1) - HERE 7. Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products (Rev 1) - HERE 8. Guideline on good pharmacovigilance practices (GVP) Module VII– Periodic safety update report(Rev1) - HERE 9. Guideline on good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies (Rev2) - HERE 10. Guideline on good pharmacovigilance practices (GVP) Module IX - Signal management - HERE 11. Guideline on good pharmacovigilance practices (GVP) Module X - Additional monitoring - HERE 12. EURD List: HERE 13. PRAC: Agendas, minutes and highlights (lists the meeting highlights, agendas and minutes from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) plenary meetings) - HERE 14. Periodic safety update reports (RSUR) - HERE 15. EU Individual Case Safety Report (ICSR) Implementation Guide - HERE 16. EudraVigilance website - HERE 17. Medical literature monitoing - HERE 18. Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the EMA - HERE 19. Periodic safety update reports: questions and answers - HERE 20. List of medicines under additional monitoring - HERE 1. Requirements on Submissions for Periodic safety update reports (PSUR) to National Competent Authorities (NCAs) products authorised via National Procedures, MRP and DCP (NAPs) - HERE
|